©The Author(s) 2021.
World J Clin Cases. Sep 26, 2021; 9(27): 8061-8070
Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.8061
Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.8061
Table 4 Comparison of the incidence of side effects between the two groups, n (%)
| Toxic side effects | Test group (n = 60) | Control group (n = 60) | χ2 | P value | ||
| Grade 1 | Grade ≥ 2 | Grade 1 | Grade ≥ 2 | |||
| Nausea | 13 (21.67) | 47 (78.33) | 18 (30.00) | 42 (70.00) | 1.087 | 0.297 |
| Vomiting | 19 (31.67) | 41 (68.33) | 24 (40.00) | 36 (60.00) | 0.906 | 0.341 |
| Loss of appetite | 24 (40.00) | 36 (60.00) | 20 (33.33) | 40 (66.67) | 0.574 | 0.449 |
| Diarrhea | 34 (56.67) | 26 (43.33) | 39 (65.00) | 21 (35.00) | 0.874 | 0.35 |
| Neutropenia | 16 (26.67) | 44 (73.33) | 22 (36.67) | 38 (63.33) | 1.386 | 0.239 |
| Leukopenia | 11 (18.33) | 49 (81.67) | 17 (28.33) | 43 (71.67) | 1.677 | 0.195 |
| Thrombocytopenia | 14 (23.33) | 46 (76.67) | 23 (38.33) | 37 (61.67) | 3.165 | 0.075 |
- Citation: Zhao FJ, Su Q, Zhang W, Yang WC, Zhao L, Gao LY. Endu combined with concurrent chemotherapy and radiotherapy for stage IIB-IVA cervical squamous cell carcinoma patients. World J Clin Cases 2021; 9(27): 8061-8070
- URL: https://www.wjgnet.com/2307-8960/full/v9/i27/8061.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i27.8061